BioMedTracker is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.


Report Library

All Reports
Datamonitor Healthcare Oncology: Small Cell Lung Cancer (SCLC) Market Spotlight

July 28, 2022

Small cell lung cancer (SCLC) is a fast-growing cancer of neuroendocrine origin that develops in the lungs and has a tendency to metastasize extensively and early in the course of the disease. It accounts for about 15% of all cases of lung cancer. Of these 15% of patients, approximately 30% are diagnosed with limited-stage disease, confined to one hemithorax. At the time of diagnosis, the majority of patients have extensive-stage disease, in which the tumor spreads beyond one hemithorax. SCLC’s standard staging procedures include CT scans of the abdomen, chest, and bone, and MRI or CT scans of the brain. 

This Datamonitor Healthcare report contains a Market Spotlight module.

Indications Covered: Small Cell Lung Cancer (SCLC)
Back to the top Back to the top